Dublin played host to the Biological Production Forum 2014. Industry experts and representatives from some of the largest Big Biopharma attended and so too did Biopharma-Reporter.com, as part of a weeklong tour of the Emerald Isle.
13-Jun-2014 - Small biotechs should consider buying mothballed plants when scaling-up according to Protein Sciences, which says an ex-Pfizer facility was key to accelerating production of its vaccine Flublok.
09-Jun-2014 - J&J says it collaborated with Novartis and GSK to install wind turbines in Cork, Ireland to substantially reduce electricity costs at its local manufacturing plants.
06-Jun-2014 - Big biopharma biosimilar development strategies vary substantially with Pfizer, Merck and Janssen split on how best to approach the burgeoning market.
03-Jun-2014 - Alexion has recalled another nine lots of Soliris after finding "visible particles" in vials of the $600,000-a-year drug for the third time in 10 months.
28-May-2014 - Janssen has mirrored Pfizer’s concerns about the scale, price and robustness of using single-use technology for high-volume production but says industry collaboration could help bring standards in place.
27-May-2014 - A government funded bioprocessing institute is helping to drive biopharma investment and retrain workers in Ireland, and Biopharma-Reporter.com visited to find out what happens in this "flight simulator for biopharma manufacturing."...
14-May-2014 - Single-use technology for high volume biomanufacturing is riddled with problems and will only be fully implemented by industry once the cost drops, according to Pfizer.
13-May-2014 - Famous for its natural beauty and the 'good craic,' Ireland is also a hub of biomanufacturing and Biopharma-Reporter is visiting the Emerald Isle to report the latest tech and trends...
13-May-2014 - Though industry has fully embraced single-use, manufacturers of such systems need to remove the risk of extractables and leachables and control the supply process according to Sartorius.
13-May-2014 - Managing over 800 CMOs could lead to quality and compliance nightmares but Valeant says it has come up with a unique cloud-based strategy.